Acquire the license to the best health content in the world
Contact Us

Drug Duo May Cut Diabetes-Related Mortality

Perindopril and indapamide combo reduced morbidity and mortality among type 2 diabetics

WEDNESDAY, Sept. 5 (HealthDay News) -- Patients with type 2 diabetes who take the angiotensin-converting enzyme inhibitor perindopril and the diuretic indapamide are at reduced risk for major vascular events compared with those who do not take the combination therapy, according to study findings published online Sept. 2 in The Lancet.

Anushka Patel, of the University of Sydney in Australia, and other investigators in the ADVANCE Collaborative Group conducted a trial of 11,140 type 2 diabetics across 215 collaborating centers in 20 countries. The participants were randomized to receive either a fixed combination of perindopril and indapamide or placebo in addition to current therapy.

The cohort was followed up for a mean 4.3 years, by which time the treatment group had a 9 percent lower risk of major macrovascular or microvascular events versus the placebo group, and the relative risks of cardiovascular death and death from any cause were reduced by 18 percent and 14 percent, respectively, relative to the placebo group.

"If the benefits seen in ADVANCE were applied to just half the population with diabetes worldwide, more than a million deaths would be avoided over five years," the authors conclude. "There is now a case for considering such treatment routinely for patients with type 2 diabetes."

Full Text (subscription or payment may be required)

Physician's Briefing